Author: Melnik, Lilia I; Garry, Robert F; Morris, Cindy A
Title: Peptide inhibition of human cytomegalovirus infection Document date: 2011_2_22
ID: 0p6x4lwx_23
Snippet: Currently available drugs to treat HCMV infection are not approved to treat pregnant women due to their potential high toxicity. HCMV infected neonates are treated with these toxic compounds only in cases of high morbidity. The antiviral peptide-based agents that may be developed as a result of this study would not require activation by virally encoded proteins, further phosphorylation by cellular enzymes or incorporation into the growing viral D.....
Document: Currently available drugs to treat HCMV infection are not approved to treat pregnant women due to their potential high toxicity. HCMV infected neonates are treated with these toxic compounds only in cases of high morbidity. The antiviral peptide-based agents that may be developed as a result of this study would not require activation by virally encoded proteins, further phosphorylation by cellular enzymes or incorporation into the growing viral DNA by viral DNA polymerase as the current therapeutics do. Such peptide therapeutics would be predicted not to provoke drug-induced resistance that is a significant problem with existing FDAapproved therapeutics to treat HCMV infection, since they employ a different mechanism of action. Our cell viability assays demonstrate that the effective peptides have no statistically significant toxicity at the highest concentrations tested in our studies (data not shown). Consequently, we do not expect adverse effects or toxicity due to treatments developed from these synthetic peptides.
Search related documents:
Co phrase search for related documents- action different mechanism and drug induce: 1
- action different mechanism and drug induce resistance: 1
- adverse effect and cell viability: 1, 2
- adverse effect and dna polymerase: 1
- adverse effect and high concentration: 1, 2, 3, 4
- adverse effect and pregnant woman: 1
- adverse effect and significant problem: 1
- adverse effect and study result: 1, 2
- adverse effect and study test: 1, 2, 3, 4
- adverse effect and toxic compound: 1
- adverse effect and toxicity adverse effect: 1, 2, 3, 4, 5, 6, 7, 8
- assay cell viability and cell viability: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78
- assay cell viability and different mechanism: 1
- assay cell viability and hcmv infection: 1
- assay cell viability and high concentration: 1, 2
- assay cell viability and high toxicity: 1, 2
- assay cell viability and study result: 1
Co phrase search for related documents, hyperlinks ordered by date